Navigation Links
Aesthera Announces Breakthrough Innovations at 2009 American Academy of Dermatology (AAD) Meeting

AAD Launches include New Technologies, Innovative Applications and New Clinical Data

SAN FRANCISCO, March 5 /PRNewswire/ -- Aesthera today announced several new launches at the upcoming 67th annual meeting of the American Academy of Dermatology in San Francisco, CA. Aligned with the company's strategic imperative to stay at the forefront of innovations in skin management, the launches will focus on the company reinforcing its leadership as the premier device based solution for acne as well as the development and commercialization of innovative technological solutions for high demand patient procedures.

Strengthening Position as Leading Acne Treatment

Strengthening its leadership position as a premier treatment in the battle against acne, Aesthera announced its latest peer reviewed clinical paper titled "Treatment of Acne with Photopneumatic Therapy," by Tina S. Alster MD et al which is published in the March 2009 issue of the Journal of Drugs and Dermatology. The paper studies the clinical efficacy of Photopneumatic Therapy for the treatment of mild to severe facial acne. "Our study noted greatest improvement in patients with severe acne. We are pleased with treatment outcomes, especially for severe acne," said study co-investigator Dr. Alster. The study was performed using Aesthera's ISOLAZ system, the only FDA cleared device for the treatment of Comedonal and Pustular Acne.

Profusion Skin Therapy for Acne, Skin Rejuvenation and Body Tightening

Aesthera will launch Profusion(TM) - (Pro=Professional and Fusion=Combination) - a breakthrough skin therapy that combines the proven clinical benefits of Photopneumatic light treatments with the delivery of Aesthera's proprietary skincare to symbiotically enhance skin treatment outcomes for acne, skin rejuvenation and body tightening. "Profusion's novel mechanism has tremendous therapeutic potential for innovative new applications. We are very excited about its clinical potential," says Vic Narurkar, MD, Chair of Dermatology at the California Pacific Medical Center (CPMC) in San Francisco, CA. "Profusion Skin Therapy is the fastest growing procedure in our practice. We routinely perform it in combination with the majority of skin treatments we offer," he adds. New applications of the technology include body tightening and skin lightening.

Additionally, Aesthera will release results of a multi-year scientific collaboration with the University of California at Riverside on Profusion Skin Therapy. "Our collaboration with the UC Riverside team reflects our commitment to basing all our treatment solutions on solid science," says Robert Anderson, PhD, Co-Founder and Chief Technical Officer of Aesthera. "We are very excited about expanding the commercial applications of Profusion Skin Therapy and are working on future applications of this novel technology," he added.

Innovative Body Tightening Technology

Moving beyond existing frameworks that address and treat body tightening, shaping and contouring Aesthera will be previewing a revolutionary approach to body tightening technology. The company's innovative body tightening platform (pending FDA clearance) will utilize a unique delivery mechanism and state of the art applicator that allows for high treatment precision and focused energy delivery. The patient benefits of Aesthera's unique solution will be fast, painless, and extremely precise treatments.

"Our continuous development and commercialization of solutions reflects our commitment to growing and strengthening our leadership position in the dermatology market," said Alon Maor, Aesthera's President & CEO.

In addition, to the above launches, Aesthera's technology will be included in over 11 podium presentations by thought leaders in dermatology.

For a complete list of podium presentations, or for more information on Profusion Skin Therapy or Isolaz Light Treatments, visit www.AESTHERA.Com,, call 877.275.4779, or email

About Photopneumatic(TM) Technology

Photopneumatic Therapy, that powers the Isolaz(TM) and Isolaz Pro(TM) system, is a proprietary combination of pneumatic energy and broad band light. Photopneumatic devices are the only laser or light based devices cleared for the treatment of inflammatory acne, comedonal acne and pustular acne. They are also cleared for the treatment of mild to moderate inflammatory acne. Photopneumatic treatments have an immediate visible impact on acne 24 - 48 hour post first treatment and are painless. Facial treatments take approximately 10 minutes, require no anesthetics or numbing creams and provide additional cosmetic benefits such as smoother appearing skin. Additionally, Photopneumatic treatments have an immediate visible impact on acne 24 - 48 hour post first treatment and are painless. Facial treatments take approximately 10 minutes, require no anesthetics or numbing creams and provide additional cosmetic benefits such as smoother appearing skin. Additionally, Photopneumatic Therapy is also cleared for the treatment of benign vascular and pigmented lesions and hair removal.

About Aesthera Corporation

Aesthera ( develops, manufactures and markets light-based aesthetic treatment systems - the Isolaz(TM) and Isolaz Pro(TM) platforms - based on proprietary Photopneumatic(TM) technology. Clinically proven to be pain-free and up to seven times faster than currently available light-based aesthetic systems, Aesthera's revolutionary systems combine the proven properties of therapeutic light with gentle pneumatic energy to more effectively work on dermal and epidermal skin targets.

    Sarvar Kothavala
    Aesthera Corp.

SOURCE Aesthera Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
2. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
3. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
4. HEI, Inc. Announces Sale of RFID Division Assets
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
6. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
7. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
8. Brooke Franchise Corporation Announces Selected July Results
9. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
11. Planet Technologies Announces Agreement to Acquire Antigen Laboratories
Post Your Comments:
(Date:6/27/2016)... ... 27, 2016 , ... TherapySites, the leading website ... Tennessee Counseling Association. This new relationship allows TherapySites to continue to ... adding exclusive benefits and promotional offers. , "TCA is extremely excited about this ...
(Date:6/27/2016)... , ... June 27, 2016 , ... ... edge technology to revolutionize the emergency ambulance transport experience for the millions of ... of how Uber has disrupted the taxi industry through the use of technology. ...
(Date:6/26/2016)... ... , ... Quality metrics are proliferating in cancer care, and are derived from ... of the beholder, according to experts who offered insights and commentary in the current ... For the full issue, click here . , For the American Society of ...
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, a ... can give their videos a whole new perspective by using the title layers ... Film Studios. , ProSlice Levels contains over 30 Different presets to choose from. ...
(Date:6/26/2016)... , ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal ... personalized through a fitness app. The fitness app plans to fix the two major problems ... offer a one size fits all type program , They don’t eliminate all ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
(Date:6/23/2016)... 2016 Roche (SIX: RO, ROG; OTCQX: RHHBY) ... Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated testing ... With this clearance, Roche is the first IVD company ... for sepsis risk assessment and management. PCT ... PCT levels in blood can aid clinicians in assessing ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... to their offering. The ... commercial environment for MedImmune to enter. The US ageing population ... to drive considerable growth for effective anti-influenza medications. The introduction ... considerably, but development is still in its infancy. ...
Breaking Medicine Technology: